Dynavax Technologies Stock Price, News & Analysis (NASDAQ:DVAX)

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies Co. (NASDAQ:DVAX) posted its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.63) by $0.03. The biopharmaceutical company earned $8.30 million during the quarter, compared to analyst estimates of $8.24 million. Dynavax Technologies had a negative net margin of 781.10% and a negative return on equity of 304.71%. The business's revenue for the quarter was up 564.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.63) earnings per share. View Dynavax Technologies' Earnings History.

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Dynavax Technologies.

5 Wall Street analysts have issued 1-year target prices for Dynavax Technologies' shares. Their forecasts range from $13.00 to $30.00. On average, they anticipate Dynavax Technologies' stock price to reach $19.00 in the next year. This suggests a possible upside of 291.8% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

Headlines about DVAX stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dynavax Technologies earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Dynavax Technologies.

Some companies that are related to Dynavax Technologies include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), United Continental (UAL), Kite Pharma (KITE), Cara Therapeutics (CARA) and Micron Technology (MU).

Dynavax Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhumbline Advisers (0.15%) and Ingalls & Snyder LLC (0.02%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.

DVAX stock was bought by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC and Rhumbline Advisers. View Insider Buying and Selling for Dynavax Technologies.

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DVAX stock can currently be purchased for approximately $4.85.

Dynavax Technologies has a market capitalization of $315.98 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.View Additional Information About Dynavax Technologies.

The official website for Dynavax Technologies is http://www.dynavax.com/.

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]